Effects of the selective bisindolylmaleimide protein kinase C inhibitor GP 109203X on P-glycoprotein-mediated multidrug resistance

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 897-905

  Gekeler, V ^a   Boer, R ^a   Uberall F ^b   Ise, W ^a   Schubert, C ^b   Utz, I ^b   Hofmann, J ^b   Sanders, K H ^a   Schachtele C ^c   Klemm, K ^a   Grunicke, H ^b  

^a ALTANA PHARMA AG   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Bisindolylmaleimide PKC inhibitor GF 109203X; Chemomodulation; Dexniguldipine HCl; Multidrug resistance; P glycoprotein; Protein kinase C

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; AZIDOPINE; DEXNIGULDIPINE; DOXORUBICIN; GLYCOPROTEIN P; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RHODAMINE 123; VERAPAMIL DERIVATIVE; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HELA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 10144224913     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.454     Document Type: Article

References (42)

1. AHMAD S AND GLAZER RI. (1993). Expression of the antisense eDNA for protein kinase Cα. attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol. Pharmacol., 43, 858-862.
2. AKIYAMA S, KOJO AT, HANOVER JA, PASTAN I AND GOTTESMAN MM. (1985). Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol. Genet., 11, 117-126.
3. BATES SE, LEE JS, DICKSTEIN B, SPOLYAR M AND FOJO AT. (1993). Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry, 32, 9156-9164.
4. BECK J, HANDGRETINGER R, DOPFER R, KLINGEBIEL T, NIETHAMMER D AND GEKELER V. (1995a). Expression of mdr1, mrp, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br. J. Haematol., 89, 356-363.
5. BECK J, GEKELER V, HANDGRETINGER R AND NIETHAMMER D. (1995b). Expression of PKC isozyme and MDR-related genes in primary and relapsed state AML. Proc. Am. Assoc. Cancer Res., 36, 335.
6. BOER R, HAAS S AND SCHÖDL A. (1994). Influence of dexniguldipine-HCl on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitizers. Eur. J. Cancer, 30A, 1117-1123.
7. HORCHERS C, ULRICH W-R, KLEMM K, ISE W, GEKELER V, HAAS S, SCHÖDL A, CONRAD J, PRZYBILSKI M AND BOER R. (1995). B9209 005, an azidoderivative of the chemosensitizer dexniguldipine-HCl photolabels P-glycoprotein. Mol. Pharmacol., 48, 21-29.
8. CHAMBERS TC, ZHENG B AND KUO JF. (1992). Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol. Pharmacol., 41, 1008-1015.
9. CHAMBERS TC, POHL J, RAYNOR RL AND KUO JF. (1993). Identification of specific sites in human P-glycoprolein phosphorylated by protein kinase C. J. Biol. Chem., 268, 4592-4595.
10. CHAUDHARY PM AND RONINSON IB. (1993). Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl Cancer Inst., 85, 632-639.
11. EPAND RM AND STAFFORD AR. (1993). Protein kinases and multidrug resistance. Cancer J., 6, 154-158.
12. FERRY DR, RUSSELL MA AND CULLEN MH. (1992). P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca-alkaloid-selective binding site. Biochem. Biophys. Res. Commun., 188, 440-445.
13. GEKELER V, FRESE G, DIDDENS H AND PROBST H. (1988). Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line. Biochem. Biophys. Res. Commun., 155, 754-760.
14. GEKELER V, WEGER S AND PROBST H. (1990). Mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles. Biochem. Biophys. Res. Commun., 169, 796-802.
15. GEKELER V, BECK J, NOLLER A, WILISCH A, FRESE G, NEUMANN M, HANDGRETINGER R, EHNINGER G, PROBST H AND NIETHAMMER D. (1994). Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann. Hematol., 69, S19-S24.
16. GEKELER V, BOER R, ISE W, SANDERS KH, SCHÄCHTELE C AND BECK J. (1995). The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem. Biophys. Res. Commun., 206, 119-126.
17. GERMANN U, CHAMBERS TC, AMBUDKAR SV, LICHT T, CARDARELLI CO, PASTAN I AND GOTTESMAN MM. (1996). Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J. Biol. Chem., 271, 1708-1716.
18. GRUNICKE H, HOFMANN J, UTZ I AND ÜBERALL F. (1994). Role of protein kinases in antitumor drug resistance. Ann. Hematol., 69, S1-S6.
19. GUPTA S, PATEL K, SINGH H AND GOLLAPUDI S. (1994). Effect of calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett., 76, 139-145.
20. r 170 000 to 180 000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res., 47, 2860-2865.
21. HARTENSTEIN JH, ARANDA J, BARTH H, KLEINSCHROTH J, RECK R, RUDOLPH C, TROSTMANN U AND SCHÄCHTELE C (1993). The design of protein kinase C inhibitors. In Perspectives in Medicinal Chemistry, Testa B, Kyburz E, Fuhrer W and Giger R. (eds) pp. 99-118. Verlag Helvetica Chimica Acta: Basle, Switzerland.
22. HEIKKILÄ J, JALAVA A AND ERIKSSON K. (1993). The selective protein kinase C inhibitor GF 109203X inhibits phorbol ester-induced morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Biochem. Biophys. Res. Commun., 197, 1185-1193.
23. HOFMANN J, GEKELER V, ISE W, NOLLER A, MITTERDORFER J, HOFER S, UTZ I, GOTWALD M, BOER R, GLOSSMANN H AND GRUNICKE H. (1995). Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem. Pharmacol., 49, 603-609.
24. KANE SE, REINHARD DH, FORDIS CM, PASTAN I AND GOTTESMAN MM. (1989). A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells. Gene, 84, 439-446.
25. KIMMIG A, GEKELER V, NEUMANN M, FRESE G, HANDGRETINGER R, KARDOS G, DIDDENS H AND NIETHAMMER D (1990). Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res., 50, 6793-6799.
26. KOHNO K, SATO S, TAKANO H, MATSUO K AND KUWANO M. (1989). The direct activation of human multidrug resistance gene (mdr1) by anticancer agents. Biochem. Biophys. Res. Commun., 165, 1415-1421.
27. KÖNIG H, PONTA H, RAHMSDORF U, BÜSCHER M, SCHÖNTHAL A, RAHMSDORF J AND HERRLICH P. (1989). Autoregulation of fos: the dyad symmetry element as the major target of repression. EMBO J., 8, 2559-2566.
28. LE PANSE R, COULOMB B, MITEV V, BOUCHARD B, LEBRETON C AND DUBERTRET L. (1994). Differential modulation of human fibroblast and keratinocyte growth by the protein kinase C inhibitor GF 109203X. Mol. Pharmacol., 46, 445-451.
29. 3H]vinblastine binding to P-glycoprotein of CCRF ADR-5000 cells. Eur. J. Pharmacol., 288, 105-113.
30. MARTINY-BARON G, KAZANIETZ MG, MISCHAK H, BLUMBERG PM, KOCHS G, HUG H, MARMÉ D AND SCHÄCHTELE C. (1993). Selective Inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J. Biol. Chem., 268, 9194-9197.
31. MIYAMOTO K, INOKO K, WAKUSAWA S, KAJITA S, HASEGAWA T, TAKAGI K AND MASAO K. (1993). Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo. Cancer Res., 53, 1555-1559.
32. MOSMANN TJ. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods, 65, 55-63.
33. NEUMANN M, WILISCH A, DIDDENS H, PROBST H AND GEKELER V. (1992). MDR hamster cells exhibiting multiple altered gene expression: effects of DNIG (B859-35), cyclosporin A and buthionine sulfoximine. Anticancer Res., 12, 2297-2302.
34. SATO W, YUSA K, NAITO M AND TSURUO T. (1990). Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun., 173, 1252-1257.
35. SCALA S, DICKSTEIN B, REGIS J, SZALLASI Z, BLUMBERG PM AND BATES SE. (1995). Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin. Cancer Res., 1, 1581-1587.
36. SZALLASI Z, SMITH CB, PETTIT GR AND BLUMBERG PM. (1994). Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol. Chem., 269, 2118-2124.
37. TOULLEC D, PIANETTI P, COSTE H, BELLEVERGUE P, GRANDPERRET T, AJAKANE M, BAUDET V, BOISSIN P, BOURSIER E, LORIOLLE F, DUHAMEL L, CHARON D AND KIRILOVSKY J. (1991). The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem., 266, 15771-15781.
38. ÜBERALL F, MALY K, EGLE A, DOPPLER W, HOFMANN J AND GRUNICKE HH. (1991). Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Res., 51, 5821-5825.
39. ÜBERALL F, WERNER-FELMAYER G, SCHUBERT C, GRUNICKE HH, WACHTER H AND FUCHS D. (1994). Neopterin derivatives together with cyclic guanosine monophosphate induces c-fos gene expression. FEBS Lett., 352, 11-14.
40. UTZ I, HOFER S, REGENASS U, HILBE W, THALER J, GRUNICKE H AND HOFMANN J. (1994). The protein kinase C inhibitor CGP 41251, a Staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 57, 104-110.
41. YU G, AHMAD S, AQUINO A, FAIRCHILD CR, TREPEL JB, OHNO S, SUZUKI K, TSURUO T, COWAN KH AND GLAZER RI. (1991). Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun., 3, 181-189.
42. YUSA K AND TSURUO T. (1989). Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res., 49, 5002-5006.